InterKrin raises $18.5M for continued work on diabetes drug
Palo Alto, Calif.-based InterKrin is developing an anti-diabetes drug. It has raised an $18.5 million in a not-yet-closed third round of funding, according to VentureWire. The round was led by Amgen and Skyline Ventures and joined by existing backers Sofinnova Ventures, OrbiMed Advisors, Asset Management, Sears Capital Management and Vivo Ventures.
Next Story: Got iBugs? Get your iPhone 2.0.1 software now
Previous Story: Tabula Digita raises round for educational games
About the Author, Eric Eldon
Eric currently covers digital media technology and business news, especially what's happening on social networks and their platforms. He also writes and edits stories about venture capital, and lots of other stuff, too. He started at VentureBeat in the spring of 2007, half a year or so after Matt Marshall left his reporting job at the San Jose Mercury News to found the site. Eric previously cofounded a startup called Writewith, that was building editorial software for newspapers and other groups of writers. The startup didn't work out, but he learned a lot.